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To date there are no published data on pharmacokinetics (PK) of
MMF in children undergoing AlloSCT. The objective of this study
is to evaluate effects of age on the PK of MMF in pediatric
AlloSCT pts. From 1/04-9/05 we enrolled 26 pediatric AlloSCT
with 23 being evaluable: mean age 7.6 yrs; wt 31.6 kg; M:F 
11:12; NBL PR (n  3), SCD (n  2), AML (CR1 [n  3], CR2
[n 1], CR3 [n 1], relapsed/induction failure [n 2]), SAA (n
4), CML CP (n  1), ALL (CR1 [n  1], CR2 [n  2], CR3 [n 
1]), HD CR2 (n  1), ALCL refractory (n  1); donor sources:
MFD (6/6 PBSC [n  6], 6/6 BM [n  2], 5/6 PBSC [n  2]), 6/6
related CB (n  1), UCB (6/6 [n  2], 5/6 [n  2], 4/6 [n  7]),
and 8/10 MUD PBSC (n  1). Cohort 1 (6 yrs) (n  8); 2 (6-12
yrs of age) (n  8); 3 (12-16 yrs) (n  7). GVHD prophylaxis
included tacrolimus (starting on day 1 or 1st day of conditioning
to maintain concentrations 5-20 ng/mL) and MMF (900 mg/m2/
dose IV Q6h starting on day1, then converted to PO [same dose]
after day 14). Serum samples for MPA assay were drawn on day
1, 7, and 14 at hour 0, 0.5, 1, 2, 3, 4, and 6 post-dose. MPA
plasma concentrations were determined by reverse-phase HPLC.
MMF dose was adjusted to maintain MPA trough 1-3.5 mg/L. The
mean CD34 cell dose/kg  25.8  105, TNC dose/kg  48 
107. Time to neutrophil (ANC 500/mm3  2 d) and platelet
engraftment (untransfused count20K  7 d) were 22 d and 39 d.
The mean f/u was 278 d. Mean MPA PK on day 14: Cmax 
12.4 mg/L, total MPA trough  0.9 mg/L, AUC0-12  32.7 mg 
hr/L, Css  2.7 mg/L, T1/2  1.5 h , Vss  1.8 L/kg, and CL 
1.4 L/kg/h at a mean MMF dose of 1080 mg/m2 IV Q6h. The
breakdown of age cohorts is shown in Table 1. Incidence of GI
adverse events attributable to MMF was 65% (nausea/vomiting
[n  12], diarrhea [n  7], abdominal pain [n  3], pneumatosis
intestinalis [n  1], colitis [n  1]). Incidence of grade II-IV
aGVHD was 59% (13/22 evaluable pts) and cGVHD was 26.3%
(5/19 evaluable pts). Kaplan-Meier probability of 1 year OS was
70.4% (CI: 49.7-91.1%). In comparison to MMF PK in adult
AlloSCT pts receiving cyclosporine/MMF (Nash et al, Biol Blood
Marrow Transplant, 2005), children have signiﬁcantly higher MMF
clearance rates (1.4 vs 0.54 L/kg/h). MMF doses 	3-fold higher
than those used in pediatric SOT recipients were required to
achieve AUC0-12  30-60 mg  h/L. Short half-life (1.5 hrs) and
rapid clearance of MMF in pediatric AlloSCT pts may be related to
a lack of enterohepatic recycling and enhanced UDP-glucurono-
syltransferase activity (Table 1).






















<6 y.o. (n  6) 12.2 1.0 18.7 34.0 2.8 1.8 1.6
6–12 y.o. (n  5) 11.8 0.4 14.8 29.5 2.5 1.1 1.4
12–16 y.o. (n  2) 14.4 1.4 17.9 39.9 3.3 1.5 0.6
Cmax  peak concentration; MPA  mycophenolic acid; AUC 
area under the curve; Css steady state concentration; T1/2
half-life; CL  clearance.
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THE ROLE OF MHC CLASS II IN CD4CD25 T CELL-MEDIATED FACIL-
ITATION OF ALLOGENEIC HEMATOPOIETIC ENGRAFTMENT AND SUP-
PRESSION OF GVHD
Hanash, A.M., Jones, A., Levy, R.B. University of Miami Miller School
of Medicine, Miami, FL.
In recent years there has been signiﬁcant interest in the potential
of CD4CD25 regulatory T cells to suppress GVHD and pro-
mote allogeneic engraftment. In a MHC-mismatched model uti-
lizing C57BL/6 (B6) T cell-depleted bone marrow and sublethally
conditioned (7.0 Gy TBI) BALB/c recipients, we have demon-
strated that co-transplanted donor CD4CD25 T cells are capa-
ble of supporting multi-potential and lineage-committed donor
progenitor activity as well as long-term chimerism and tolerance.
Little is currently understood regarding the antigen recognition
initiating regulatory cell function during hematopoietic transplan-
tation, and we have employed our in vivo model toward elucidating
the antigenic requirements involved in the initial promotion of
allogeneic engraftment. Transplanting BALB/c  B6 F1
CD4CD25 T cells (1  106) with B6 marrow (2  106) signif-
icantly increased B6 CFU-GM in BALB/c recipients seven days
post-BMT (P  .001 vs. BM alone), demonstrating that donor
CD4CD25 T cells did not require alloreactivity to support
hematopoietic progenitors. Furthermore, B6 CD4CD25 T cells
failed to augment MHC-disparate C3H/HeJ CFU-GM in BALB/c
recipients (P 	 .05 vs. BM alone), suggesting that donor
CD4CD25 T cells might require recognition of syngeneic
MHC for progenitor support. Indeed, augmentation of donor
CFU-GM was abrogated when B6 CD4CD25 T cells were
co-transplanted with B6-MHC class II/ marrow into BALB/c
recipients (P 	 .05 vs. BM alone). CD4CD25 T cell-mediated
augmentation of donor chimerism two months post-BMT was also
abrogated by co-transplantation with MHC II/ marrow. In
order to compare the role of MHC class II in progenitor support
vs. suppression of GVHD, a model of CD8-mediated GVHD was
utilized: co-transplanted BALB/c CD4CD25 T cells were able
to prevent the GVHD mediated by highly puriﬁed BALB/c CD8
T cells in B6-wt recipients, but failed to control the GVH reaction
that occurred in B6-MHC II/ recipients. Therefore, while do-
nor CD4CD25 T cells required co-transplantation with synge-
neic MHC II to support donor hematopoietic progenitors, alloge-
neic recipient MHC II was required for suppression of GVHD. In
conclusion, donor CD4CD25 T cells capable of promoting
long-term engraftment and tolerance may have distinct antigenic
requirements from those responsible for GVHD suppression, and
clinical protocols for allogeneic transplantation involving
CD4CD25 T cells should account for their distinct antigenic
requirements.
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ROLE OF IL-2, IL-7, AND IL-15 IN ALLOGENEIC GRAFT-VS-LEUKEMIA
AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA IN A NOD/scid CHIMERIC
MURINE MODEL
Cipkala, D.A., Hendey, L., Boyer, M.W. Columbus Childrens Research
Institute, Columbus, OH.
We studied the GVL effects of human alloreactive CTL against
ALL in a chimeric NOD/scid mouse model. CTL were generated
from random blood donor PBMCs stimulated with the 697 human
ALL cell line and supplemented with IL-2, 7, or 15. CD8
positive T cells comprised the majority of the cultures in each
group: 46% for IL-2, 52% for IL-7, and 45% for IL-15 cultured
CTL (n  13). CTL grown in each cytokine resulted in similar in
vitro cytotoxicity: IL-2 41.3%, IL-7 37.7%, IL-15 45.3%, n 
12-15, and had statistically similar intracellular perforin and gran-
zyme-B expression. IL-7 and IL-15 CTL had statistically higher
bcl-2 levels than IL-2 CTL suggesting better anti-apoptosis and
survival potential. NOD/scid mice were injected with 697 ALL
cells followed by 5  106 CTL. Mice were sacriﬁced seven days
following CTL injection and residual leukemia was measured in
the bone marrow and spleen via ﬂow cytometry. There were two
groups of experiments with different degrees of leukemia engraft-
ment seen at day 21. In one group (low engraftment) mice not
receiving CTL had a baseline leukemia burden of 2.01% and
0.15% in the bone marrow and spleen, respectively (n  15). Mice
treated with IL-15 cultured CTL had a reduction in tumor burden
to 0.2% (n  13, P  .01) and 0.05% (n  13, P  .01) in bone
marrow and spleen, respectively. Those treated with IL-2 or IL-7
cultured CTL showed no signiﬁcant difference in leukemia burden
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in either the bone marrow (IL-2 1.28%, IL-7 5.97%) or spleen
(IL-2 0.4%, IL-7 0.33%). One experiment was performed with
puriﬁed CD8 positive cells from IL-15 CTL with BM leukemia of
0.037% (P  .01) demonstrating a role for CD8 positive T cells in
the GVL effect. In the second group (hi engraftment) mice not
receiving CTL had a baseline BM leukemia burden of 10.0% (n 
17), and no CTL treatment group had statistical differences: IL-15
11.5% (n  14), IL-2 9.1% (n  7), and IL-7 7.0% (n  5).
Further experiments in the high engraftment model compared PBS
vs IL-2 (20,000 IU) injected IP every 12 hrs for 6 doses. Control
IL-2 injection had no effect on BM leukemia (8.4%, n  10) nor
did IL-15 CTL IL-2 IP (10.3%, n 5) while IL-2 CTL IL-2
IP was statistically lower ( 0.58%, n  6, P  .02). In conclusion
allogeneic CTL grown with IL-15 exerted IL-2 independent GVL
effects on a low leukemia burden while those grown with IL-2
exerted IL-2 dependent GVL effects on a higher leukemia burden,
and this model should be helpful for understanding GVL mecha-
nisms.
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CHRONIC OR ACUTE? GVHD BEYOND DAY 100
Couriel, D.R., Saliba, R.M., Ghosh, S., de Lima, M., Giralt, S.,
Khouri, I., Andersson, B., Mickler, K., Caldera, Z., Hsu, Y.,
Neumann, J., Hymes, S., Kim, S., Champlin, R. Blood and Marrow
Transplantation, The University of Texas M.D. Anderson Cancer Cen-
ter, Houston, TX.
Objective: To assess the clinical and prognostic implications of
the timing of acute GVHD (aGVHD). Introduction: The syn-
drome of a-GVHD has been deﬁned as GVHD occurring before
day 100 post transplant, although it is clear that it can occur later.
This raises the question of potential historical misclassiﬁcation of
a-GVHD as chronic GVHD (c-GVHD). In this study, we assess
the extent of this misclassiﬁcation, and evaluate risk factors as well
as clinical and prognostic differences between GVHD before (clas-
sic aGVHD) and after day 100 (late aGVHD). Methods: Retro-
spective evaluation of database and records on all matched sibling
transplants (n  128) was performed at UT MDACC between
1/00 and 2/02. Clinical manifestations of all GVHD diagnosed
after day 100 post transplant were reviewed to distinguish between
late a-GVHD and c-GVHD. Results: A total of 67/128 patients
were diagnosed with c-GVHD. Upon review of medical records,
30/67 (45%) were found to be late aGVHD, and the remainder
true cGVHD. Of the 30 patients with late aGVHD 9 had pro-
gressing GVHD through day 100, these were reclassiﬁed as classic
aGVHD. We evaluated risk factors for developing late aGVHD in
patients who were alive by day 100, and had no prior diagnosis of
GVHD. Only a later engraftment (ANC 	500 beyond day 12) was
associated with a higher incidence of late aGVHD, while age, gender,
malignancy, disease status at transplant, type of preparative regimen,
cell type or CD3, 4 or 8 infused did not impact the incidence.
Compared to classic aGVHD, the late group had a signiﬁcantly
higher proportion of grade 2-4 GVHD (85 vs 61%, P  .03) with
similar proportion of grade 3-4 aGVHD (29 vs 27%, P .50). There
was a trend to better response (CR/PR) to ﬁrst line immunosuppres-
sion in patients with late aGVHD (81% vs 63%, P .13). The overall
survival (OS) and non-relapse mortality (NRM) since the diagnosis of
GVHDwere substantially better in patients with late aGVHD (OS 70
vs 29%), P  .01; NRM 16 vs 39%, P  .06). Conclusions: (1) The
current chronological deﬁnition of acute GVHDmay lead to misclas-
siﬁcation of late aGVHD as chronic GVHD. This could have impli-
cations in interpreting the current knowledge and literature on
GVHD. (2) There is a trend to better response to therapy and better
survival in patients developing aGVHD beyond day 100. Thus, tim-
ing of aGVHD may affect its outcome.
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CRITICAL ROLE FOR CCR1:CCL5 (RANTES) RECEPTOR LIGAND INTER-
ACTIONS IN MODULATING ALLOGENEIC T CELL RESPONSES FOLLOW-
ING STEM CELL TRANSPLANTATION
Choi, S.W.1, Hildebrandt, G.C.2, Silva, I.A.1, Olkiewicz, K.M.1,
Chensue, S.W.1, Liu, C.3, Chaudhary, M.N.1, Fisher, J.1, Lane, T.E.4,
Cooke, K.R.1 1. University of Michigan, Ann Arbor, MI; 2. University
of Regensburg, Regensburg, Germany; 3. University of Florida, Gaines-
ville, FL; 4. University of California, Irvine, Irvine, CA.
Acute GVHD and leukemic relapse are the most serious com-
plications of allogeneic (allo) stem cell transplantation (SCT). Re-
cruitment of activated T cells to host target tissues (GVHD) or
sites of leukemic inﬁltration (GVL) is likely mediated by chemo-
kine receptor:ligand interactions. CCR1 is a chemokine receptor
that binds to CC chemokines including RANTES (CCL5) and is
expressed on a variety of cells including T cells, monocytes and
macrophages. Using a well-established murine SCT model
(B63B6D2F1) and mice deﬁcient in CCR1, we examined the
contribution of CCR1 expression on donor cells to allo T cell
responses in vitro and to GVH and GVL effects in vivo. Lethally
(1100 cGy) irradiated B6D2F1 mice received SCT from syngeneic
(syn) (B6D2F1) or allo (B6) CCR1/ or CCR1/ donors. Syn
recipients all survived, whereas animals receiving allo-SCT from
CCR1/ donors developed signiﬁcant GVHD. By contrast, allo-
SCT with CCR1/ donor cells resulted in signiﬁcantly im-
proved survival (92% vs. 50%) and less severe clinical GVHD by
day 35 compared to allo-CCR1/ controls. GVL effects were
assessed by adding 500 P815 tumor cells (H-2d, syn to host) to the
SC inoculum on day 0. Syn recipients all died from tumor inﬁl-
tration by day 15. Although allo-SCT recipients effectively re-
jected their tumor, mice receiving CCR1/ SCT had signiﬁ-
cantly improved leukemia free survival (45% vs. 5%) by day 60
compared to allo controls. At higher tumor doses, signiﬁcant GVL
activity remained in CCR1/ SCT recipients, but the survival
advantage was lost. Surprisingly, allo T cell responses in vivo
revealed that day 7 splenic T cell expansion and serum IFN levels
were signiﬁcantly lower following CCR1/ SCT (P  .01).
Proliferation and IFN secretion were also reduced by 70% when
CCR1/ T cells were stimulated with host antigens in vitro,
whereas CTL activity remained equivalent to CCR1/ cells.
The reduction in proliferation was not secondary to a migration
defect, but was dependent on interactions between CCR1 and
RANTES; antibody neutralization of RANTES reduced prolifer-
ation of CCR1/ T cells in a dose-dependent manner. Finally,
we found that GVHD mortality was also less when RANTES/
mice or chimeric wild type mice reconstituted with RANTES/
BM cells were used as recipients in a second, MHC-disparate SCT
model (P  .05). Collectively these data demonstrate a critical role
for CCR1 in donor T cell responses following SCT that contribute
to both GVHD and GVL.
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A CRITICAL ROLE OF SEMA4D (CD100) IN REDUCING GRAFT-VERSUS-
HOST DISEASE IN A MURINE MAJOR MISMATCH TRANSPLANT
Duran-Struuck, R.1, Rogers, C.1, Clouthier, S.1, Gatza, E.1, Liu, C.2,
Kumanogoh, A.3, Reddy, P.1, Ferrara, J.L.M.1 1. University of Mich-
igan Cancer Center, Ann Arbor, MI; 2. University of Florida College of
Medicine, Gainesville, FL; 3. Osaka University, Osaka, Japan.
Sema4D (CD100) is a 150 kDa transmembrane protein member
of the class IV semaphorin family that has immunomodulatory
functions, and is essential for the activation and differentiation of
antigen speciﬁc T cells. We investigated the effects of CD100
expression on T cells in allotransplantation. In vitro studies showed
that T cells from genetically engineered CD100/ mice ex-
panded ten fold less than B6 wild type (wt) T cells (10800 1229.9
vs. 1600  258 cpm P  .01) in response to BALB/c allogeneic
stimulators. We then evaluated the role of CD100 in vivo utilizing
a well characterized experimental model of graft-versus-host dis-
ease (GvHD) where donor and recipient are mismatched at both
major and minor histocompatibility antigens [B6 (H2b)3BALB/c
(H2 d)]. Recipient BALB/c animals were irradiated with 8 Gy and
transplanted with 5.0  106 million bone marrow (BM) cells from
B6 animals together with 0.5 million T cells from either B6 wild
type (wt) or CD100 / donors. As shown in Table 1, at day 60
after transplant, mice that received CD100 / T cells had sig-
niﬁcantly less clinical GvHD scores and improved survival (P 
.08) compared to allogeneic wt T cells. Recipients of CD100/
T cells also demonstrated signiﬁcantly reduced GvHD pathology
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